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ABSTRACT
Background Myeloid- derived suppressor cells (MDSC) 
are a functional myeloid cell subset that includes myeloid 
cells with immune suppressive properties. The presence 
of MDSC has been reported in the peripheral blood of 
patients with several malignant and non- malignant 
diseases. So far, direct comparison of MDSC across 
different diseases and Centers is hindered by technical 
pitfalls and a lack of standardized methodology. To 
overcome this issue, we formed a network through the 
COST Action Mye- EUNITER ( www. mye- euniter. eu) with the 
goal to standardize and facilitate the comparative analysis 
of human circulating MDSC in cancer, inflammation and 
infection. In this manuscript, we present the results of 
the multicenter study Mye- EUNITER MDSC Monitoring 
Initiative, that involved 13 laboratories and compared 
circulating MDSC subsets across multiple diseases, using 
a common protocol for the isolation, identification and 
characterization of these cells.
Methods We developed, tested, executed and optimized 
a standard operating procedure for the isolation and 
immunophenotyping of MDSC using blood from healthy 
donors. We applied this procedure to the blood of almost 
400 patients and controls with different solid tumors and 
non- malignant diseases. The latter included viral infections 
such as HIV and hepatitis B virus, but also psoriasis and 
cardiovascular disorders.
Results We observed that the frequency of MDSC in 
healthy donors varied substantially between centers 
and was influenced by technical aspects such as the 
anticoagulant and separation method used. Expansion of 
polymorphonuclear (PMN)- MDSC exceeded the expansion 
of monocytic MDSC (M- MDSC) in five out of six solid 
tumors. PMN- MDSC expansion was more pronounced 
in cancer compared with infection and inflammation. 
Programmed death- ligand 1 was primarily expressed 
in M- MDSC and e- MDSC and was not upregulated as a 
consequence of disease. LOX-1 expression was confined 
to PMN- MDSC.
Conclusions This study provides improved technical 
protocols and workflows for the multi- center analysis of 
circulating human MDSC subsets. Application of these 
workflows revealed a predominant expansion of PMN- 
MDSC in solid tumors that exceeds expansion in chronic 
infection and inflammation.
BACKGROUND
Myeloid- derived suppressor cells (MDSCs) 
can expand in the peripheral blood of patients 
with several malignant and non- malignant 
diseases as a consequence of altered myelo-
poiesis. MDSCs represent a still relatively 
new functional myeloid cell subset and there 
are few methods available to compare this 
subset across different diseases.1 2 MDSCs 
are commonly subdivided into two main 
subtypes, based on their morphology, density 
and cell surface markers: polymorphonuclear 
MDSC (PMN- MDSC) and monocytic MDSC 
(M- MDSC). An additional subtype, which 
lacks macrophage and granulocyte markers, 
is called early- stage MDSC (e- MDSC) and 
it has been shown to accumulate in several 
disease settings.3 4 The main biological func-
tion attributed to MDSC is immune suppres-
sion of T cells through several mechanisms 
such as production of arginase 1, inducible 
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nitric oxide synthase, indoleamine dioxygenase, cycloox-
ygenase and reactive oxygen species.5
Bronte et al published in 2016 an extensive paper 
containing recommendations for the study of human and 
mouse MDSC; the paper provided a useful list of markers, 
gating strategies and functional tests to be used for MDSC 
study.4 This was definitely one of the first solid milestones 
in MDSC study standardization. However, still there is the 
need to further refine the process by comparing MDSC 
frequencies and functions across multiple diseases. A 
significant problem in the field is the lack of robust and 
reproducible consensus protocols and markers that would 
allow the comparative analysis of MDSC in different 
disease settings and multicenter trials.
In order to overcome these limitations, the authors of 
this paper formed a study group within the COST Action 
Mye- EUNITER ( www. mye- euniter. eu). The main goal of 
Mye- EUNITER was to further standardize and facilitate 
the study of human MDSC in multiple human diseases. 
Within this network, we developed an international 
research program (Mye- EUNITER MDSC Monitoring 
Initiative, Mye- MMI), which involved 13 European labs 
and performed the first pan- European cross comparative 
study on human MDSC, with almost 400 patients analyzed. 
This study uses a consensus standard operating procedure 
(SOP)- like protocol for the isolation and phenotyping of 
human circulating MDSC. Analysis of peripheral blood 
mononuclear cells (PBMC) from healthy donors showed 
that technical variables, such as the anticoagulant and 
separation method used, cause artifactual variabilities in 
the frequency of MDSC. When using an optimized and 
standardized protocol and comparing results to healthy 
control subjects, we observed a significant expansion of 
PMN- MDSC in solid cancers that was less pronounced 
in non- malignant chronic infectious and inflammatory 
disease settings. Expression of programmed death- ligand 
1 (PD- L1) was mainly observed in M- MDSC and e- MDSC, 
while PMN- MDSC express Lectin- like oxidized low- 
density lipoprotein receptor-1 (LOX-1).
METHODS
Human blood collection and description of patient cohorts
Lab 1 (Essen, Germany)
Peripheral blood was prospectively collected from 
treatment- naïve patients with primary head and neck 
cancer (HNC) and from healthy donors. Patients with 
synchronous carcinoma in another location or concomi-
tant systemic infectious disease were excluded. All control 
samples are age matched to the patient group.
Lab 2 (Edinburgh, UK)
Peripheral blood (10 mL) was obtained from breast 
cancer patients from National Health Service, Edinburgh, 
Scotland, UK. The exclusion criteria for all patients with 
cancer at baseline included systemic metastatic disease, 
any inflammatory disorder and active infection or immu-
nocompromised status not related to cancer. All the 
patients recruited were chemotherapy and radiotherapy 
naive before collection. All control samples are age 
matched and sex matched to the patient group.
Lab 3 (Nijmegen, The Netherlands)
Peripheral blood samples were collected from healthy 
individuals and glioma patients undergoing neurosur-
gical resection or biopsy for intracranial tumors at the 
Radboud University Medical Center (Radboudumc). 
Glioma patients receive dexamethasone as part of 
their treatment. All patients had histologically proven 
brain tumors diagnosed by neuropathologists of the 
Radboudumc. The tumors were classified according 
to WHO 2016 Classification of tumors of the Central 
Nervous System, and encompassed low- grade diffuse 
astrocytoma, isocitrate dehydrogenase (IDH)- mutant 
(WHO grade II), oligodendrogliomas, IDH- mutant and 
1 p/19q- codeleted (WHO grade II, WHO grade III), and 
glioblastomas (grade IV). The healthy donors were anon-
ymous and not age and sex matched.
Lab 4 (Heidelberg, Germany)
Peripheral blood samples (30 mL) were obtained from 
21 melanoma patients of stage I–IV who were seen at the 
Skin Cancer Center (University Medical Center Mann-
heim, Germany) from February 2017 to March 2018. 
Tumor stages were determined according to the eighth 
edition of the American Joint Committee on Cancer 
(AJCC) classification. All the patients recruited were not 
treated within the last 6 months before blood collection. 
For control samples, mononuclear cells were isolated 
from peripheral blood obtained from the Institute of 
Transfusion Medicine and Immunology, Medical Faculty 
Mannheim, Heidelberg University, German Red Cross 
Blood Service Baden Württemberg–Hessen (Mannheim, 
Germany) after informed consent. All control samples 
are age matched to the patient group.
Lab 5 (Belgrade, Serbia)
No blood samples from lab five are presented in this 
manuscript.
Lab 6 (Ankara, Turkey)
Peripheral blood samples (~10 mL) were obtained from 
healthy volunteers, and newly diagnosed, treatment- naïve 
colorectal cancer patients. All control samples are age 
matched and sex matched to the patient group.
Lab 7 (Warsaw, Poland)
For control samples, mononuclear cells were isolated from 
peripheral blood obtained from female healthy individ-
uals from Military Institute of Medicine. Peripheral blood 
(10 mL) was obtained from ovarian cancer patients from 
Military Institute of Medicine (Warsaw, Poland). The 
exclusion criteria for all patients with cancer at baseline 
included systemic metastatic disease, any inflammatory 
disorder and active infection or immunocompromised 
status not related to cancer. All the patients recruited were 
chemotherapy and radiotherapy naive before collection. 
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All control samples are age matched and sex matched to 
the patient group.
Lab 8 (Essen, Germany)
For control samples, mononuclear cells were isolated 
from the peripheral blood obtained from healthy volun-
teers at the Institute of Virology with their agreement to 
use the blood for the Mye- MMI study. Peripheral blood 
(10 mL) was obtained from non- treated patients with 
hepatitis B virus (HBV) infection from Clinic for Gastro-
enterology and Hepatology, University Hospital Essen. All 
control samples are age matched to the patient group.
Lab 9 (Paris, France)
For the study on HIV-1 infection, peripheral blood was 
collected on heparin from eleven antiretroviral treated, 
aviremic individuals living with HIV and from eleven 
healthy donors. The inclusion criteria for the people living 
with HIV-1 were as follows: plasma HIV RNA levels of <50 
copies/mL for at least 24 months. Exclusion criteria were 
as follows: inflammatory diseases, infection with HIV-2, 
active co- infections, <200 CD4 cells, recent (<3 months) 
vaccinations. The healthy donors were anonymous and 
not age and sex matched.
Lab 10 (Lisbon, Portugal)
Peripheral blood (10 mL) was obtained from HIV-1 
-infected subjects and healthy volunteer blood donors. 
The HIV-1- infected patients were studied immediately 
after diagnosis before starting antiretroviral therapy. 
All patients featured detectable plasma HIV RNA levels 
(802–8 61 828 copies/mL) and have broad CD4 T cell 
count distribution (10–866 cells/µL). The other exclu-
sion criteria for HIV-1- infected patients included HIV-2 
infection, no evidence of opportunistic infection or 
tumor, and no recent vaccinations (<3 months). All 
control samples are age matched to the patient group.
Lab 11 (Krakow, Poland)
For control samples, mononuclear cells were isolated 
from peripheral blood obtained from healthy individuals 
through blood donation center or research lab. Periph-
eral blood (10 mL) was obtained from psoriasis patients 
from Dept. of Dermatology, Zeromski Hospital, Krakow, 
Poland. The severity of the psoriatic skin lesions was 
assessed according to the Psoriasis Area Severity Index 
score. Patients on UV therapy, systemic or local corticoste-
roid treatment were excluded from the studies. Healthy 
control subjects had no clinical signs of dermatologic 
or inflammatory diseases. All control samples are age 
matched to the patient group.
Lab 12 (Stockholm, Sweden)
Healthy adults were intramuscularly vaccinated with one 
dose of the yellow fever vaccine (Stamaril, Sanofi) or the 
tick- borne encephalitis vaccine (Encepur, GlaxoSmith-
Kline). Peripheral venous blood was collected at the day 
prior to vaccination and at day 2 after vaccination. Prevac-
cination controls and postvaccination samples from the 
same individuals were compared.
Lab 13 (Bergen, Norway)
Peripheral blood was collected from patients with acute 
chest pain admitted at Haukeland University Hospital 
(Bergen, Norway). The patients were included consec-
utively in two cohorts. We included subjects above 18 
years of age who were hospitalized due to recent- onset 
chest pain of suspected cardiac origin and who received 
acetylsalicylic acid during ambulance transport or when 
arriving at the hospital, on suspicion of cardiovascular 
disease (CVD). Patients who were on immunomodu-
lating medications, for example, corticosteroids, or with 
severe infections, were excluded from the study. Patients 
in whom CVD was confirmed were defined as acute chest 
pain patients with CVD. The patients where no CVD could 
be detected were defined as acute chest pain patients 
without CVD.
We initially planned to use and we strived for age and 
sex matched non- CVD donors for this study. However, due 
to time restriction and the available donors at the period 
of sampling, age and sex matching was not achieved for 
all patients.
Detailed clinical information for all patients involved in 
the study can be found in online supplementary table 1.
Isolation of PBMC according to standardized protocol
In phase I of this study (compare figure 1), participants 
used either heparin, trisodium citrate or Ethylenedi-
aminetetraacetic acid (EDTA) anticoagulated blood. 
Blood was processed within 1 hour after blood sampling 
in all phases of this study. Before separation blood was 
admixed with the same volume of phosphate- buffered 
saline (PBS) and overlayed on 1.077 g/mL separation 
medium (Biocoll, Merck Millipore; Ficoll- Paque, GE 
healthcare; Pancoll, PAN- Biotech; Lymphoprep, Stem-
cell Technologies). Density centrifugation was performed 
at room temperature 400xg, 30 min without accelera-
tion and brake. Afterward plasma was aspirated until 
5 cm above PBMC fraction. PBMCs were collected using 
disposable Pasteur pipette into 50 mL centrifugations 
tubes (Falcon 352096). To remove thrombocytes, cells 
Figure 1 Schematic representation of the Mye- MMI study. 
See manuscript text for details on the different phases and 
steps. The SOP- like protocol for MDSC immunophenotyping 
that was generated in the context of this study is available 
from the corresponding author on reasonable request. 
MDSC, Myeloid- derived suppressor cells; Mye- MMI, Mye- 
EUNITER MDSC Monitoring Initiative; PD- L1, programmed 
death- ligand 1; SOP, standard operating procedure.
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were washed by filling the tube up with PBS followed by 
centrifugation at 300xg for 8 min at room temperature 
until the supernatant was clear. After the last washing 
step, cells were resuspended in Roswell Park Memorial 
Institute (RPMI) 1640 culture medium supplemented 
with 100 IU/mL penicillin, 100 mg/mL streptomycin 
and 10% (v/v) heat- inactivated FCS for counting. To 
study the influence of the anticoagulants all participants 
received the same batch of heparin, trisodium citrate or 
EDTA collection tubes and Safety- Multifly- needle 21G (all 
Sarstedt, Nümbrecht, Germany) that were shipped from 
the core lab (lab 1) to the participating centers (phase 
IIA, figure 1).
In phase III of the study, the samples were collected in 
a harmonized fashion using trisodium citrate as anticoag-
ulant and using Biocoll as the separation medium.
Immunophenotyping of MDSC subsets by flow cytometry
For characterization of MDSC subsets in phase I and II of 
the study, all participants used the same antibody clones with 
free choice of fluorochromes. In brief, 1×106 cells in a total 
volume of 50 µL were stained with CD15 clone HI98, CD14 
clone MOP9, CD33 clone WM53, CD11b clone ICRF44, 
HLA- DR clone G46- 6n and lineage cocktail including CD3 
clone SK7, CD19 clone H1B19, CD20 clone 2H7 (not manda-
tory) and CD56 clone NCAM16.2 in the presence of FcR 
block in Fluorescence- activated cell sorting (FACS) buffer 
(PBS/2% bovie serum albumine (BSA)) for 20 min at 4°C. 
FMO control was used for CD11b and HLA- DR. Cells were 
washed with FACS buffer, centrifuged at 400xg for 5 min and 
resuspended in 200 µL FACS buffer for acquisition.
In phase III, participants included the functional marker 
PD- L1 clone 29E.2A3 and LOX-1 clone 15C4. Isotypes were 
used as negative controls. Isolation of PBMC, MDSC anti-
body labeling and data acquisition was locally performed in 
the participating centers. Because of technical constraints 
with multiparameter options at local flow cytometers and 
because of limited choices of commercially available fluo-
rochromes for LOX-1, CD11b could not be included in the 
second step. Locally acquired data files were uploaded to a 
protected data server and centrally analyzed in the core lab 
(Essen, Germany) to ensure uniform conditions for gating 
for all samples from all centers.
T cell suppression assay
For validation of MDSC suppressive capacity, we used a previ-
ously published protocol of flow cytometry MDSC sorting 
and suppression of polyclonally stimulated autologous cancer 
patient- derived T cells.6 In brief, CD3 depleted PBMC from 
cancer patients were labeled with CD66b clone 80H3, CD33 
and HLA- DR and sorted on lowest flow rate for HLA- DR-/
CD33high (M- MDSC), HLA- DR-/CD33dim/CD66b+ (PMN- 
MDSC), HLA- DR-/CD33dim/CD66b- (e- MDSC).
The positively selected CD3 T Lymphocytes were labeled with 
10 µM Proliferation Dye eFluor 450 (CPDye405) according to 
manufacturer instructions (eBioscience, Frankfurt am Main, 
Germany). T cells were stimulated with coated CD3 (1 µg/
mL, clone OKT-3, eBioscience) and CD28 (2 µg/mL, clone 
CD28.2 Beckman coulter) in L- lysine and L- arginine free 
RPMI medium (Thermo Fisher Scientific) supplemented with 
150 µM L- Arginine, 0.218 mM L- Lysine hydrochloride (both 
Sigma- Aldrich, Taufkirchen, Germany), 100 IU/mL penicillin, 
100 mg/mL streptomycin and 10% (v/v) heat- inactivated FCS. 
Autologous MDSC- subsets were added in a T- cell: MDSC ratio 
of 2.5:1. CPDye405 intensity was analyzed by flow cytometry 
after 4 days of coculture and proliferation. Supernatants of 
the coculture were collected and IFN-γ measured by ELISA 
according to manufacturer’s protocol.
Patient and public involvement
Patients were not involved in the design of the study and the 
analysis and discussion of the data. The background of this 
study and the overall concept of Mye- EUNITER Initiative 
are shared with the general public by two publicly available 
videos. Videos are currently available at www. Mye- EUNITER. 
eu.
Analysis and statistics
Data from all participants were collected, uploaded to a 
protected data server and centrally analyzed in the core lab 
(Essen, Germany). GraphPad Prism Software (GraphPad Soft-
ware, La Jolla, California, USA) was used for statistical analysis 
and significance was assessed with Mann- Whitney, Wilcoxon 
matched- pairs signed rank or Kruskal- Wallis test. Results were 
considered significant at *p≤0.05, **p≤0.01 and ***p≤0.001.
RESULTS
Development of consensus protocols and execution of training 
schools
Within this network, we developed an international research 
program (Mye- MMI), which involved 13 European labs. 
The Mye- MMI study was divided into three phases: during 
phase I participants designed and agreed to use a SOP for 
the immunophenotyping and analysis of MDSC in the blood 
of human patients and controls (Phase IA, figure 1) The Mye- 
MMI network organized a training school, where scientists 
from all participating labs executed the SOP and trained 
together in the core lab (Essen, Germany) using the same 
samples; the outputs of the training school indicated that the 
SOP was reproducible and the variance among users minimal 
(phase IB, figure 1). The training school also provided all 
participants with practical and hands- on experience with the 
SOP. T cell suppression is a hallmark of MDSC function. We 
used a previously published protocol to assess the suppres-
sion of cancer patient- derived T cells by autologous circu-
lating MDSC.6 This protocol was trained in the Essen core 
lab with selected participants and subsequently used for func-
tional validation using patients with HNC and patients with 
melanoma. All these steps enabled the network to perform 
the study in different labs and geographical locations using 
a commonly agreed SOP for immunophenotyping and 
common assays validating MDSC function.
Expansion of circulating MDSC subsets in cancer exceeds 
expansion in infectious and inflammatory diseases
After development of an initial consensus protocol for the 
immunophenotyping of circulating MDSC and execution 
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of a training school, the trained researchers performed 
MDSC immunophenotyping in their own Centers (phase 
IC, figure 1). In each center, a particular cancer type or 
infection or inflammatory disease was investigated. Data 
files (.fcs format) from all patients and control subjects were 
uploaded to a protected server at the coordinating Center 
(Essen) and centrally analyzed. Figure 2 shows an example of 
the employed gating strategy. Based on previous experience 
in the participating centers, we derived a sequential gating 
strategy that identifies the three major human circulating 
MDSC subsets with no overlap between subsets. In a first step, 
we determined the frequency of PMN- MDSC, M- MDSC and 
e- MDSC in six different types of cancer, major viral infections, 
psoriasis, a mixed cohort of patients with inflammatory CVDs 
and in patients that received the yellow fever or the tick- borne 
encephalitis vaccine. In each center, an independent group 
healthy donor controls was analyzed (see online supplemen-
tary table S1 for patient and healthy donor characteristics). 
At this stage, the anticoagulant and the blood separation 
medium were free of choice to the lab.
In most cancer types, we observed a substantial induction of 
PMN- MDSC frequency over healthy controls (figure 3A). No 
statistically significant increase of PMN- MDSC was observed in 
patients with infectious and inflammatory diseases, although 
a tendency for higher frequency of PMN- MDSC was observed 
in some diseases, in agreement with previous reports.7 In 
patients with cancer, the induction of the PMN- MDSC subset 
exceeded expansion of other MDSC subsets (figure 3A). 
When compared with healthy donors the PMN- MDSC 
frequency was induced in 5/6 cancer types (figure 3B). In 
contrast, M- MDSC frequency was only significantly induced 
in glioma or was even reduced in breast cancer. A particular 
induction of M- MDSC was observed in patients with inflam-
matory CVD and after vaccination confirming previous find-
ings,8 but did not change in any other conditions. With the 
exception of glioma and viremic HIV-1, e- MDSC frequencies 
were not significantly altered between healthy donors and 
patients.
Although our study was focused on the immunomon-
itoring and immunophenotpying of MDSC in different 
Figure 2 Flow cytometry gating of the three major subsets of human circulating MDSC. PBMCs were isolated from the 
peripheral blood of patients and healthy donor controls by density gradient centrifugation in 12 different participating centers 
and according to a harmonized protocol. Use of predefined clones was mandatory. In a centralized analysis, MDSC subsets 
were classified as CD15+/CD14-/CD33dim/HLA- DRneg=PMN- MDSC (P4), CD15-/CD14+/CD33pos/HLA- DRneg=M- MDSC (P6) 
and CD15-/CD14-/CD11b+/CD33dim/HLA- DRneg as e- MDSC (P8).4 An example for the gating strategy is shown (head and neck 
cancer patient). Note that all MDSC subsets are negative for the lymphocyte lineage markers CD3, CD19 and CD56 (CD20 not 
mandatory). MDSC, myeloid- derived suppressor cells; PBMCs, peripheral blood mononuclear cells; PMN, polymorphonuclear.
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diseases, we sought to test and confirm the T cell suppressive 
activity of the MDSC subsets under investigation. Employing 
previously published protocols6 we tested the immunosup-
pressive capacity of MDSC isolated from patients with HNC 
and melanoma using identical protocols after execution of 
a training school. In line with earlier findings,6 and in both 
tumor entities tested, PMN- MDSC were superior to M- MDSC 
and e- MDSC in suppressing the function of polyclonally stim-
ulated autologous T cells (figure 4).
Identification of technical and experimental variables that 
influence immunomonitoring of MDSC
Intercenter analysis of data presented in figure 3 revealed 
an interesting variability in the frequency of PMN- MDSC 
Figure 3 Frequency of the three MDSC subsets in malignant and non- malignant disease. For each center the frequency of the 
three MDSC subsets was determined for patients and the respective local healthy controls. Staining procedure and gating were 
performed according to figure 1. (A) Median frequency of MDSC compared with healthy donor’s controls (set as value 1) and 
(B) total frequency within the PBMC are shown. Mean values with SD are shown. Mann- Whitney U test was used for statistical 
analysis. Results were considered significant at *p≤0.05, **p≤0.001 and ***p≤0.0001. CVD, cardiovascular disease; HBV, 
hepatitis B virus; MDSC, Myeloid- derived suppressor cells; PBMCs, peripheral blood mononuclear cells.
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Figure 4 Suppressive activity of MDSC subsets. Suppressive activity of the MDSC subsets was confirmed in two independent 
laboratories using a shared and previously published protocol.6 (A) Cell proliferation dye labeled Responder T cells from patients 
were stimulated with plate- bound CD3 and CD28 mAb in the presence or absence of autologous MDSC (T cell: MDSC ratio of 
2.5:1). Lymphocyte proliferation was measured at day 4 and analyzed centrally. Relative proliferation to stimulated T cell without 
MDSC (set as 100%) and mean values are shown. (B) Levels of IFNγ were determined in supernatants of cocultures consisting 
of T cells activated by plate- bound CD3/CD28 with and without additions of MDSC. IFNγ was determined after 4 days by 
ELISA. Relative release was calculated to stimulated T cells without MDSC. Mean values are shown. Wilcoxon signed- rank test 
was used for statistical analysis. Results were considered significant at *p≤0.05, **p≤0.001 and ***p≤0.0001. Gating strategy 
data are from a patient with head and neck cancer. IFNγ, interferon-γ; M- MDSC, monocytic myeloid- derived suppressor cells; 
PMN, polymorphonuclear.
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in healthy donors (figure 3B, upper panels). Frequency 
of this MDSC subset in healthy donors varied between 
0.08% (lab 1) and 1,8% (lab 3) in the cancer Centers and 
between 0.3% (lab 11) and 1.9% (lab 12) in the infection 
& inflammation Centers. We considered it unlikely that 
this difference is based on biological differences between 
healthy donors in the respective Centers. A reanalysis of 
the underlying data and protocols further revealed that, 
despite standardized immunolabelling and analysis, the 
participating centers used different anticoagulants and 
separation media for isolation of MDSC from venous 
blood of healthy donors and patients. In order to test for 
a potential effect of the anticoagulant (sodium citrate, 
EDTA, heparin), we purchased the three types of blood 
collection tubes at the coordinating Center (lab 1) and 
shipped them to eight participating Centers for further 
use (phase IIA, figure 1). Centers obtained venous blood 
from healthy donors into three different collection tubes 
and used their preferred separation medium for MDSC 
isolation. MDSC labeling was performed according to the 
standardized consensus protocol and data files were sent 
to the coordination Center for centralized analysis. Anal-
ysis of MDSC frequencies showed that the type of antico-
agulant had little influence on the frequency of M- MDSC 
and e- MDSC. In contrast, a clear increase in PMN- MDSC 
frequency was observed when heparin was compared with 
sodium citrate (figure 5A). This increase was observed 
for all types of separation medium. In order to test for a 
potential effect of the separation medium, we reanalyzed 
the data of healthy donors with the separation medium 
being the variable factor (figure 5B). Results revealed 
an increased frequency of PMN- MDSC when Ficoll was 
used as the separation medium (figure 5B, left column). 
Samples prepared via Biocoll showed the lowest frequency 
of M- MDSC in healthy donors. For PMN- MDSC Biocoll 
and Lymphoprep showed the lowest frequencies. Based 
on these data we concluded that a combination of Biocoll 
and sodium citrate would provide lowest frequencies of 
MDSC in healthy donor blood samples; these data were, 
therefore, used to refine the SOP by including precise 
indications on the separation medium and anticoagulant 
to be used (phase IIB, figure 1).
Validation of the refined SOP and comparison with previous 
dataset
In order to confirm the utility of standardization of the 
isolation procedure, five participating Centers volun-
teered to repeat the analysis shown in figure 3 using the 
refined SOP (phase IIIA, figure 1). Figure 6 shows the 
level of variance in healthy donors for the original data 
(figure 3, phase IC) and the variance of data with the 
harmonized isolation procedure (phase IIIA). Data show 
that choice and standardization of blood collection tubes 
and separation medium reduced PMN- MDSC frequency 
in healthy donors, further improved intercenter compara-
bility of results and reduced differences in MDSC counts 
between healthy control cohorts from different Centers.
PD-L1 is primarily expressed in mononuclear MDSC and is not 
upregulated as a consequence of disease
LOX-1 has been suggested as a marker associated with 
suppressive activity of PMN- MDSC.9 PD- L1 is expressed on 
myeloid cells and considered as an important biomarker 
and functional target in current immunotherapies.10 
In the final step of our study (phase IIIB, figure 1), we 
tested the expression of both markers in five participating 
centers.
Quantitative analysis of expression levels showed that 
PD- L1 is primarily expressed on M- MDSC and e- MDSC 
(figure 7 and online supplementary figure S1). In contrast, 
PD- L1 is absent or expressed at very low levels on PMN- 
MDSC. As expected, LOX-1 is expressed on PMN- MDSC 
and absent on M- MDSC and e- MDSC (figure 7B, online 
supplementary figure S2). It is important to note that in 
all tested diseases and conditions both markers were not 
upregulated in patients over healthy controls.
DISCUSSION
Since their initial identification, MDSCs have received substan-
tial consideration from immunologists, who performed 
several studies to elucidate their immunopathological role 
in cancer, inflammation and infectious diseases.11–14 In addi-
tion, MDSCs are considered as major cellular mediators of 
resistance to cancer immunotherapy and may serve as poten-
tial future biomarkers to predict response to conventional 
and immune- based cancer therapy.15 Thus, precise and reli-
able immunomonitoring of MDSC, even in intercenter anal-
yses, is of utmost importance.
Human circulating MDSCs are normally isolated from 
whole blood after density gradient centrifugation and subdi-
vided into at least three different subsets (granulocytic PMN- 
MDSC, monocytic M- MDSC and myeloid precursor- like 
e- MDSC) using flow cytometry.6
The main limitation of the current studies on human 
MDSC lies in the extreme variability in the protocols used to 
extract, identify and phenotype these cells. Variable isolation 
procedures, antibody panels and gating strategies are used 
to isolate and characterize human MDSC. Previous reports 
already highlighted the need for marker and gating harmo-
nization4 16 and outlined technical variables that could affect 
MDSC immunomonitoring.17 A recommendation paper 
was published in order to suggest minimal characterization 
standards when researching MDSC.4 However, also in those 
reports no consensus strategy for MDSC preparation, isola-
tion and immunophenotyping is provided and an accepted 
gating strategy for enumeration of non- overlapping human 
MDSC subsets does not exist until now. These obstacles make 
it nearly impossible to directly compare MDSC data sets 
between published studies.
In this study, we developed a consensus protocol for the 
isolation, identification and immunophenotypic charac-
terization and analysis of human MDSC. After centralized 
hands- on training, this protocol was executed in the partic-
ipating Centers, followed by a centralized flow cytometry 
analysis that utilized a uniform gating strategy. Our initial 
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analysis on malignant and non- malignant infectious/
inflammatory disease patients revealed that PMN- MDSC 
are significantly expanded in malignant disease with 5/6 
cancer types (ie, Glioma as well as head and neck, breast, 
colorectal and ovarian cancer) showing statistically signifi-
cant upregulation even with our relatively small sample size 
per cancer type, and consistent to what is already reported 
in the literature.6 18–22 No statistically significant induc-
tion of PMN- MDSC frequency was found in melanoma. 
Interestingly, and in contrast to cancer, this induction of 
PMN- MDSC was not observed in patients with infection 
and inflammation. For M- MDSC and e- MDSC we did not 
Figure 5 Identification of further technical variables in MDSC immunomonitoring. Participating centers stained for MDSC 
subsets in healthy donor controls. Beforehand every participant received the identical batch of blood collection tubes. From 
the same donor sodium citrate-, EDTA and heparin blood was collected and PBMC were stained for MDSC subsets in PBMC. 
Lymphocyte separation medium was free of choice. MDSC frequency was determined in the core lab as described for figure 2. 
Influence of anticoagulants (A) and lymphocyte separation medium (B) on total frequency of putative ‘MDSC subsets’ in healthy 
individuals with mean and SD is shown. Kruskal- Wallis was used for statistical analysis. Results were considered significant 
at *p≤0.05, **p≤0.001 and ***p≤0.0001. M- MDSC, monocytic myeloid- derived suppressor cell; PBMC, peripheral blood 
mononuclear cell; PMN, polymorphonuclear.
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find such significant changes in most disease entities. We 
acknowledge that the sample size could be responsible for 
the lack of statistically significant expansion of MDSC in 
some types of disease. Nevertheless, the comparative pan- 
disease analysis in our study unequivocally shows that PMN- 
MDSC expansion in solid cancers exceeds expansion of this 
MDSC subset in infectious and inflammatory diseases and 
also exceeds the relative expansion of M- MDSC in cancer. 
These data partially challenge previously published data 
that reported robust MDSC expansion in infections and 
non- malignant inflammatory diseases such as psoriasis, 
HIV, HBV and CVDs.23–27
Figure 6 Standardization of anticoagulant and separation medium reduces intercenter variability of PMN- MDSC frequencies. 
All participants used sodium citrate as anticoagulant and Biocoll as separation medium and determined the frequency of 
PMN- MDSC in healthy donor controls. Data were compared with data obtained for figure 2. (A) Frequency of PMN- MDSC in 
Step1 (figure 2, free choice of anticoagulant and separation medium) and step 2 (sodium citrate and Biocoll) from all healthy 
blood donors in the five centers is shown (plus mean and SD). (B) The mean frequency was determined for each of the five 
participating centers and (C) % cv was calculated. In all panels the comparison to step 1 (data from figure 2) is shown. F test 
was used for statistical analysis. Results were considered significant at *p≤0.05 and ****p≤0.0001. PBMC; peripheral blood 
mononuclear cell.
Figure 7 Expression of molecules associated with T cell suppression expression of PD- L1 and LOX-1 on MDSC subsets in 
patients and healthy donor controls was determined using the harmonized flow cytometry labeling protocol, Biocoll as standard 
separation medium and sodium citrate as standard anticoagulant. Flow cytometry analysis was performed in the core lab to 
ensure standardized gating. Staining intensity of PD- L1 (A) and LOX-1 (B) on MDSC- subsets was determined in five different 
disease settings. Delta median (median signal intensity of antibody minus median signal intensity of isotype control) is shown. 
Data are depicted as mean and SD is shown. CVD, cardiovascular disease; M- MDSC, monocytic myeloid- derived suppressor 
cells; PD- L1, programmed death- ligand 1; PMN, polymorphonuclear.
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In this context, it is interesting to note the very divergent 
levels of MDSC expansion reported in the literature. The use 
of different methodologies and techniques to isolate MDSC 
could potentially lead to technical, rather than biologically 
caused differences among labs. It is a particular strength of 
our study that, by using a SOP- like protocol, harmonized 
reagents and antibodies, core Center analysis and a uniform 
gating strategy, we were able to facilitate a comparative anal-
ysis of human MDSC expansion across many different disease 
types.
Our study also revealed the importance of further tech-
nical variables during blood collection and separation. 
These findings were triggered by initial observations that 
showed substantial differences in the frequency of MDSC 
in healthy donors across the different Centers (see PMN- 
MDSC frequencies in healthy donors in figure 3B). These 
differences suggested that additional technical variables, 
not standardized in the original SOP, could affect the 
results. We then decided to analyze the anticoagulant and 
gradient separation medium variables, by performing 
additional experiments; results indicated that different 
anticoagulants and separation media can alter the base-
line frequency of MDSC in healthy donors. In particular 
the combination of sodium citrate as anticoagulant and 
Biocoll as stratification solution allowed for the lowest 
MDSC frequencies in healthy donors.
Anticoagulants can affect the frequency of MDSC in 
human blood as already reported by Apodaca et al; the 
authors compared the total number of M- MDSC in blood 
of healthy donors collected using EDTA or Heparin 
and observed a significant difference between the two 
anticoagulants.17
We included these two additional standardized variables 
in the SOP and repeated the experiments in a selected 
number of centers, showing a reduced degree of variance 
among healthy donors across centers. It is worth noting 
that by this approach we obtained PMN- MDSC frequen-
cies well below 1% in four out of five Centers. Again, a 
great variability in MDSC, and in particular PMN- MDSC 
frequency is reported in the literature.4 17 28
In the final phase of our study, we also evaluated the 
expression of PDL1 and LOX-1, two surrogate suppressive 
functional markers associated with M- MDSC and PMN- 
MDSC, respectively. Our data confirmed the restricted 
expression of LOX-1 on PMN- MDSC as previously 
reported for circulating PMN- MDSC9 and PMN- MDSC in 
cancer tissues.29 On a per cell basis the expression level of 
LOX1 was not different between PMN- MDSC extracted 
from healthy donor controls and cancer patients. It is, 
however, important to note that LOX1- positive PMN- 
MDSC were substantially expanded in cancer patients 
over healthy controls. This is also in line with previous 
studies9 that showed an expansion of this LOX-1- positive 
subset in the unseparated blood of cancer patients. In 
contrast, strong expression of PD- L1 was restricted to 
M- MDSC and e- MDSC and similar to LOX-1, on a per 
cell basis, the expression was not substantially induced in 
patients with cancer.
PD- L1 is a promising target for checkpoint blockade 
immunotherapy. From our data we may assume that this 
type of immunotherapy will primarily co- target M- MDSC 
in cancer patients. Most likely, additional and distinct ther-
apeutic interventions will be required to target human 
PMN- MDSC. In the context of these considerations, we 
are convinced that the use of standardized protocols for 
immunomonitoring of MDSC subsets and their associ-
ated functional molecules will aid future patient selection 
and stratification for treatment.
CONCLUSION
In summary, our optimized study design allows us to 
conclude that expansion of PMN- MDSC exceeds expan-
sion of other MDSC subsets in cancer and is more 
pronounced in solid tumors as opposed to various 
infectious and inflammatory diseases. In addition, we 
report several technical and analytical aspects that will 
guide the future analysis of MDSC, an important poten-
tial cellular resistance mechanism in current cancer 
immunotherapies.
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